Search Results for "Crizotinib Src Kinase"

16:37 EDT 30th May 2015 | BioPortfolio

Matching Channels

Polo like kinase Plk 1

Polo-like kinase (Plk) is an important cell cycle regulatory kinase that has been implicated in a multitude of cell cycle events. Plks form a family of four different proteins that regulates many as...

MAP kinase kinase MEK Inhibitors

The mitogen activated protein kinases (MAPKs) are conserved proteins that regulate cell growth, division and death.  The MAPK pathway has emerged as the crucial route between membrane-bound Ras...

Bcr Abl and Src Kinase Inhibitors

Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between the long arms of the chromosomes 9 and 22 t...

Checkpoint kinase 1 CHK 1

Progression through the cell cycle is monitored by surveillance mechanisms known as cell cycle checkpoints. Dysfunction in cell cycle checkpoints leads to genomic instability and contributes to tumo...

Kinases Raf Inhibitors

The Ras-Raf-MEK-ERK (ERK) pathway is a logical therapeutic target because it represents a common downstream pathway for several key growth factor tyrosine kinase receptors which are often mutated or...

Matching News

Crizotinib (Xalkori) for ALK-positive, locally advanced or metastatic, non-small cell lung cancer – first line

Crizotinib is intended to be used to treat previously untreated non-small cell lung cancer (NSCLC) that has locally advanced or metastasised and expresses the anaplastic lymphoma kinase (ALK) gene. If...

Two oncology successes for Pfizer

Pfizer has received two boosts in oncology as Xalkori gets a new breakthrough therapy designation from the FDA, and its leukaemia offering inotuzumab ozogamicin sees positive Phase III trial results. ...

Merck and Pfizer to co-promote cancer drug

Merck KgaA and Pfizer have agreed to co-promote the latter’s lung cancer treatment Xalkori, and form a new alliance that combines their oncology sales organisations. Xalkori (crizotinib) was first a...

Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4; MEKKK4)

Mouse studies suggest

Novartis' Lung Cancer Drug Gets European Approval

Novartis announced that the European Commission has approved Zykadia (ceritinib) to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) prev...

EMD Serono begins co-promotion of Pfizer's cancer drug Xalkori in US

Merck subsidiary EMD Serono as part of its global strategic alliance with Pfizer has started co-promoting the latter's anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib) in the US.

Zykadia™

Class: Biological Therapy Generic Name: ceritinib Trade Name: Zykadia™ ? For which conditions is this drug approved? Zykadia is approved for the treatment of patients with metastatic non-small cell...

Novartis receives EU approval for Zykadia to treat ALK+ NSCLC

Novartis has received approval from the European Commission for its Zykadia (ceritinib) to treat adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCL...

Matching PubMed Articles

When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs.

Crizotinib is an orally active multi-target tyrosine kinase inhibitor which is the standard of care in patients with anaplastic lymphoma kinase translocated non-small-cell lung cancer. Common adverse ...

Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer.

To the Editor: In the study reported by Shaw et al. (Nov. 20 issue),(1) crizotinib appears to be more potent against the gene encoding ROS1 proto-oncogene receptor tyrosine kinase (ROS1) than against ...

Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer.

To the Editor: In the study reported by Shaw et al. (Nov. 20 issue),(1) crizotinib appears to be more potent against the gene encoding ROS1 proto-oncogene receptor tyrosine kinase (ROS1) than against ...

Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer.

Crizotinib, a c-MET/ALK inhibitor, has exhibited antitumor efficacy in different types of cancers. However, studies regarding Crizotinib in pancreatic cancer have been limited. Thus, we investigated t...

Analysis of ERBB Ligand-Induced Resistance Mechanism to Crizotinib by Primary Culture of Lung Adenocarcinoma with EML4-ALK Fusion Gene.

Using cell line-based assays, the secretion of erythroblastic leukemia viral oncogene homologue (ERBB) ligands has been reported to contribute to resistance against crizotinib in lung cancer with the ...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement